Smallpox, money pox, and the vaccines they will try to frighten you into receiving
The WHO released a clever statement to introduce the idea of mass money pox vaccination to the public:
The World Health Organization (WHO) maintains that the growing monkeypox outbreak remains “containable,” and that there’s no immediate need for mass vaccination against the orthopoxvirus; since May 7, a total of 131 confirmed cases and 106 suspected cases have been reported in countries where it usually does not spread. (Reuters)
immediate need. Let that statement ferment in your unconscious. It
seems like a benign sentence, but implicit in it is the idea that soon there may well be a need to mass vaccinate the population against money pox, a disease that has never before spread due to casual contact.
I don’t think we even know the actual mortality rate for money pox. Has a westerner ever died from it?
Could this possibly be the same money
pox that occurs in Africa? If so, how did it suddenly appear in so
many countries at once? This fact alone—its novel, never-before-seen
pattern of spread, should make us question whether it is a biowarfare
agent being seeded deliberately. Probably not meant to kill us, maybe
not even to harm us much. We can’t tell yet, based on the minimalist
info coming out of our esteemed public health agencies. Perhaps it’s
here just to nudge us to get another shot?
Below I give you the basics on smallpox, monkeypox and the newest vaccines coming to a clinic near you:
1. If there is a money pox vaccine (and FDA has apparently approved one that the army helped develop) it has not been tested for efficacy, because there have not been enough human cases to do so.
Efficacy testing requires
that you vaccinate people and then see how many cases of the disease
occur in the vaccinated versus the placebo group. If you were able to
vaccinate a million people but disease frequency was such that you
couldn’t even get a handful of cases occuring, you cannot perform an
Instead, in order to get vaccines approved
or authorized, antibody tests are done that are claimed to demonstrate
the presence of immunity. But oft times (as in the COVID or anthrax
vaccines) the antibody that is selected for this purpose may not be a
reliable indicator of immunity…as admitted at the booster VRBPAC meeting
by FDA staff and committee members.
2. The smallpox
vaccine is said to be 85% effective against monkeypox…but without many
human monkeypox cases, that 85% number cannot possibly have been
3. The smallpox vaccine causes a huge number of
myocarditis cases and other known cardiac problems, making it almost
certainly more dangerous than the risk of getting monkeypox. One in 220
recipients developed an obvious case of myocarditis in a US military study published in 2015, and one in 30 got a subclinical case.
Why would ANYONE take such a high risk of cardiac damage to avoid a miniscule risk of money pox? Only because they were misinformed.
Smallpox vaccine, when used routinely in babies, was considered the
most dangerous vaccine available. It led to the deaths of several people per million administrations.
I received smallpox vaccines in 1951 and 1972 and believe I had
insignificant reactions. I expect I am fully immune to smallpox. Tests
done in people in 2003 published in NEJM suggested immunity was
6. The US smallpox vaccine last used routinely in
civilians was the NY Department of Health version, and it was made
similarly to the vaccine of the 1700s. Infectious fluid from a related
orthopox virus was scratched on the belly of a calf, and then when new
vesicles developed the material was collected as the vaccine substrate,
and could only be minimally purified.
7. Ever wonder why the
smallpox vaccine is scratched on while all others are injected? Because
it was so dirty, contaminated with other animal viruses and unspecified
materials, which might cause a serious infection if injected beyond the
8. It was hoped, 20-30 years ago, that a newer, cleaner,
purified vaccine would avoid the many severe side effects. Two newer
vaccines (ACAM 2000, purified from the NY DOH Dryvax vaccine
and MVA) were purchased by the Clinton and Bush administrations for all
Americans. It turned out, unfortunately, that the cardiac side effects
persisted. They were due to the actual vaccine antigen, not to the
‘junk.’ The MVA (Modified Vaccinia Ankara) vaccine, which is less
reactogenic but may be less effective than ACAM2000, had its US name
changed to Jynneos, and has now been designated the official MoneyPox vaccine.
Regarding ACAM2000 and the licensing of Jynneos, FDA said in 2019 (on page 4):
is contraindicated for use in individuals with severe immunodeficiency
who are not expected to benefit from the vaccine… In 2003, a monkeypox
outbreak was confirmed in the U.S. This was the first time human monkeypox was
reported outside of the African continent. (Not true but close—Nass) Currently, there is no approved treatment
or licensed vaccine for monkeypox, although the Advisory Committee on
Practices (ACIP) recommends that ACAM2000 be used for prevention of
monkeypox in individuals at high risk of exposure (e.g., lab workers who
handle monkeypox virus). Thus, there is an unmet need for a monkeypox
9. The US government initiated a
smallpox vaccine program in 2003 that rapidly failed—people refused to
be vaccinated due to high rates of heart attacks, heart failure and
myocarditis. The National Academies of Science (NAS) wrote a series of
about 8 critical “Letter Reports” on the government program, and the
magazine Science wrote about the final report here. However, both the NAS and Science
pulled their punches, failing the fully emphasize the dangers and to
reflect the widespread skepticism about the program, which used a
dangerous vaccine for a nonexistent or at least unproven threat.
10. According to Medpage,
CDC says both Jynneos and ACAM2000 vaccines will be available to
respond to the money pox event. Yet even CDC currently admits that the
chance of myocarditis is huge (greater than one in 200 vaccine
recipients) from the ACAM2000 vaccine, in an MMWR from November 2021:
ACAM2000 is replication-competent, there is a risk for serious adverse
events (e.g., progressive vaccinia and eczema vaccinatum) with it;
myopericarditis also occurs with ACAM2000 (estimated rate of 5.7 per
1,000 primary vaccinees based on clinical trial data), but the
underlying mechanism is unknown (7,8).
the same MMWR article , the CDC perhaps inadvertently admitted it had
no reliable evidence for either safety or efficacy:
The effectiveness of JYNNEOS was inferred from the immunogenicity of JYNNEOS in clinical studies and from efficacy data from animal challenge studies. [But humans do not necessarily respond the same as lab animals—Nass] Occurrences of serious adverse events are expected to be minimal because JYNNEOS is a replication-deficient virus vaccine. However, because the mechanism for myopericarditis following receipt of ACAM2000 is thought to be an immune-mediated phenomenon, it is not known whether the antigen or antigens that precipitate autoantibodies [causing myocarditis or other adverse events—Nass] are present in JYNNEOS as well.
Later down, CDC admits again that it has no idea what it is doing with the Jynneos vaccine:
a correlate of protection has not been established and there is no
known antibody titer level that will ensure protection, titer results
should be interpreted with caution in such cases to avoid providing a
false sense of security.
12. Despite knowing there is virtually no reliable information about how the vaccine might prevent monkeypox nor how safe it is, the Quebec government has begun rolling out the vaccine for the prevention of money pox. According to CBC:
smallpox vaccine — which hasn’t been routinely offered in Canada for
decades — will be offered to those at high risk of contracting the
disease, such as those who have been in contact with confirmed cases.
top health officer] Boileau said the province has access to hundreds of
doses at the ready, but vaccination will only occur after a
recommendation from public health. It will not be open to the general
13. Whitney Webb wrote last week about two of the Beltway Bandits poised to make yet another killing on money pox, Emergent BioSolutions and SIGA Technologies.
I will be adding to this post.